AcelRx Pharma Posts Narrower Loss In Q3; To Acquire Lowell Therapeutics

AcelRx Pharmaceuticals, Inc. (ACRX) reported a third-quarter loss per share of $0.07 compared to a loss of $0.10, prior year. Analysts polled by Thomson Reuters expected the company to report a loss per share of $0.07, for the quarter. Analysts' estimates typically exclude special items. Net loss was $8.4 million compared to a loss of $8.9 million.

Revenue increased to $1.86 million from $1.37 million, a year ago. Analysts on average had estimated $1.9 million in revenue.

Separately, AcelRx Pharmaceuticals announced the execution of a definitive merger agreement to acquire Lowell Therapeutics, Inc. Lowell is a privately held company developing Niyad, a regional anticoagulant for the dialysis circuit during continuous renal replacement therapy for acute kidney injury patients.

The deal is valued at approximately $32.5 million plus net cash acquired and certain other adjustments, and includes approximately $26.0 million of contingent consideration. An amount of shares of AcelRx common stock valued at approximately $6.5 million is anticipated to be issued to Lowell securityholders at the closing.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Delta Air Lines said it sees weather-related flight cancelations as AT&T and Verizon readies for 5G roll out in and around the vicinity of major U.S. airports. Most of the other airlines also confirmed the same as the implementation of the new C-Band 5G service is expected to interfere with the working of onboard aircraft instruments. Financial services firm Morgan Stanley (MS) reported Wednesday a profit for the fourth quarter that increased 10 percent from last year, reflecting 7 percent revenue growth amidst strength in Wealth Management and Investment Management business segments. Bank of America Corp. (BAC) reported Thursday that net income applicable to common shareholders for the fourth quarter grew 30 percent to $6.77 billion from last year's $5.21 billion, with earnings per share increasing to $0.82 from $0.59 in the prior year, reflecting strong operating leverage as revenues...
Follow RTT